EG00229 is a small molecular inhibitor of VEGF-A interaction with NRP-1.29 (link)–31 (link) For cell culture studies, EG00229 (R&D Systems, #4931) was dissolved in DMSO to produce a 100 mM (50 mg/ml) stock. For in vivo studies, EG00229 was diluted to 2 mM (1 mg/ml) in 20% captisol, a non-toxic delivery vehicle.57 (link) In brief, 40% captisol (RC-0C7-020, CyDex Pharmaceuticals, Lawrence, KS, USA) was prepared in sterile water by stirring overnight at 25°C followed by filter sterilization. The 40% captisol solution (50 ml) was diluted 1:1 with sterile water and supplemented with 0.5 ml of 1N acetic acid to create 20% captisol solution. The 50 mg/ml EG00229 stock was diluted 1:50 into 20% captisol solution and 0.2 ml was injected intraperitoneally three times per week (M, W, F) to achieve a final level of 10 mg/kg body weight.